New oral therapeutic agents are needed for patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy.
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis / Danese, Silvio; Neurath, Markus F; Kopoń, Adam; Zakko, Salam F; Simmons, Timothy C; Fogel, Ronald; Siegel, Corey A; Panaccione, Remo; Zhan, Xiaojiang; Usiskin, Keith; Chitkara, Denesh. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - 18:11(2020), pp. 2526-2534.e9-2534.e9. [10.1016/j.cgh.2019.12.032]
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
Danese, Silvio;
2020-01-01
Abstract
New oral therapeutic agents are needed for patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
